Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)

Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Christian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, Martin Birkhäuser, Heike A. Bischoff-Ferrari, Diana Frey, Reto W. Kressig, Olivier Lamy, Kurt Lippuner, Petra Stute, Norbert Suhm, Serge Ferrari
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2017-08-01
Edice:	Swiss Medical Weekly
Témata:	bisphosphonates denosumab fractures osteoporosis Treatment
On-line přístup:	https://www.smw.ch/index.php/smw/article/view/2352
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!